Research Topics
Species | Gail V MatthewsSummaryAffiliation: University of New South Wales Country: Australia Publications
| Collaborators
|
Detail Information
Publications
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews
Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
Hepatology 48:1062-9. 2008..This study confirms current treatment guidelines that recommend a TDF-based regimen as the treatment of choice for HIV/HBV coinfection, but does not demonstrate any advantage of HBV combination therapy in this short-term setting...
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapyGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
AIDS 20:863-70. 2006..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy...- The management of HIV and hepatitis B coinfectionGail Matthews
Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia
Curr Opin Infect Dis 20:16-21. 2007..This review highlights the most important recent developments in the management of HIV and hepatitis B virus coinfection... 
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia
AIDS 23:1707-15. 2009..To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort...- Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovirGail V Matthews
HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
Antivir Ther 12:119-22. 2007..The safety and efficacy of tenofovir in HIV/HBV cirrhosis has not been previously described... - Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis CG V Matthews
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Clin Infect Dis 48:650-8. 2009..Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC... - HIV and hepatitis C coinfectionGail V Matthews
Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
J Gastroenterol Hepatol 23:1000-8. 2008..New therapies, including HCV protease and polymerase inhibitors, are in development and may widen therapeutic options for HIV-HCV-coinfected individuals into the future... - Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infectionJason Grebely
The Kirby Institute for Infection and Immunity in Society, University of New South Wales UNSW, Sydney, Australia
AIDS 26:1653-61. 2012..This study evaluated early virological decline during recent HCV therapy in HIV-uninfected individuals receiving pegylated interferon (PEG-IFN) monotherapy and HIV-infected individuals receiving PEG-IFN/RBV... - Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infectionMaryam Alavi
The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
J Gastroenterol Hepatol 27:957-65. 2012..Data on the effect of HCV treatment on mental health among injecting drug users (IDUs) are limited. We assessed mental health during treatment of recently acquired HCV, within a predominantly IDU population... - Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug usersJason Grebely
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
J Hepatol 55:76-85. 2011..We assessed 80/80 adherence (≥80% of PEG-IFN doses, ≥80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC)... - Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionJason Grebely
National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
Hepatology 52:1216-24. 2010..Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes... - Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionJason Grebely
Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
Hepatology 55:1058-69. 2012..Conclusion: Reinfection and superinfection can occur during treatment of recent HCV and are associated with poor social functioning and ongoing IDU. ALT levels may be a useful clinical marker of reexposure... - Effective treatment of injecting drug users with recently acquired hepatitis C virus infectionGregory J Dore
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Gastroenterology 138:123-35.e1-2. 2010..We evaluated the efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV... - Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in ThailandAnchalee Avihingsanon
The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
AIDS Res Ther 9:6. 2012..abstract:.. - Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppressionDavid M Iser
Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
AIDS 25:197-205. 2011.... - Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected IndividualsGail V Matthews
Kirby Institute, University of New South Wales, Sydney, Australia
PLoS ONE 8:e61297. 2013..The aim of this study was to examine serological change including quantitative biomarkers in HIV-HBV coinfected patients initiating HBV active antiretroviral therapy (ART)... - Treatment of acute HCV infectionJason Grebely
Viral Hepatitis Clinical Research Program, National Center in HIV Epidemiology and Clinical Research, University of New South Wales, Corner Boundary and West Streets, Darlinghurst, Sydney, NSW 2010, Australia
Nat Rev Gastroenterol Hepatol 8:265-74. 2011..This Review highlights current knowledge of the epidemiology, diagnosis, natural history and treatment of acute HCV infection, including proposed recommendations for the assessment and treatment of this infection... - Future of hepatitis C therapy: development of direct-acting antiviralsGregory J Dore
Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia
Curr Opin HIV AIDS 6:508-13. 2011.... - Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis CG V Matthews
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
Clin Infect Dis 52:803-11. 2011..The extent to which these separate epidemics overlap is unknown... - Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyJ Grebely
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
Drug Alcohol Depend 107:244-9. 2010..Decisions about whether to initiate treatment for recently acquired HCV were mainly driven by clinical factors, rather than factors related to sociodemographics or injecting behaviors... - Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, AustraliaFengyi Jin
National Centre in HIV Epidemiology and Clinical Research, Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
Sex Transm Infect 86:25-8. 2010..We report prevalence, incidence and risk factors for HCV infection in community-based cohorts of HIV-negative and HIV-positive homosexual men in Sydney... - Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern AfricaGail V Matthews
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
AIDS 25:1727-35. 2011..To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART)... - Treatment for hepatitis C virus infection among current injection drug users in AustraliaGail Matthews
Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Australia
Clin Infect Dis 40:S325-9. 2005..Further studies are under way to examine outcomes of treatment for HCV among clients undergoing treatment for drug dependency who have chronic HCV infection and among current IDUs with acute and newly acquired HCV infection... - Invasive amebiasis in men who have sex with men, AustraliaDamien Stark
St Vincent s Hospital, Darlinghurst, New South Wales, Australia
Emerg Infect Dis 14:1141-3. 2008..e., Japan, Taiwan, and Republic of Korea. We report locally acquired invasive amebiasis in Sydney, Australia, exclusively in MSM... - Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et alGail V Matthews
AIDS 21:2112-3. 2007 - Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individualsPeter A Revill
Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
AIDS 21:1701-10. 2007..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy... - Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'Gail V Matthews
AIDS 21:777-8. 2007 - Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort studyGail V Matthews
Department of HIV Medicine, Chelsea Hospital, London, UK
AIDS 16:53-61. 2002..Clinical trial data is required to confirm these findings...